Business Wire

'True Stories of Investing' - flatexDEGIRO drives financial education with high-quality documentation

28.1.2022 12:48:00 EET | Business Wire | Press release

Share

With "True Stories of Investing", flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest-growing retail online broker collaborates with award-winning documentary maker, New Amsterdam, and Discovery, to demystify investing. The documentary premieres on Discovery's channels across Europe starting this weekend and showcases important lessons every retail investor needs to know. In four episodes, renowned journalists, professors, behavioral scientists and investors challenge some of the biggest misconceptions about investing by examining historical events and the mechanisms at work.

Frank Niehage, CEO of flatexDEGIRO: "It is our mission to retailise capital markets and empower private individuals to invest in a self-determined and sustainable way. As Europe's leading online broker, we feel responsible for making trading more simple, more informed, and more secure for our customers. With this innovative documentary, we take financial education one step further. We are very proud to be the first online broker to collaborate with New Amsterdam and Discovery on this important topic and to be part of this outstanding and informative production.

" Muhamad Chahrour, CFO of flatexDEGIRO and CEO of DEGIRO: "In 2021, we have optimised our pricing structure, including commission-free trading of stocks and ETFs in different markets, significantly extended our product offering and invested heavily into IT to provide the highest stability and security on our platforms. Together with a strong push for educational marketing, this unmatched combination of best-in class platforms, products and prices should encourage 250 million people in Europe to invest appropriately and sustainably."

Award-winning director Lyangelo Vasquez delves into the world of investing. The documentary explains the difference between active and passive investing, an exploration that starts with the friendly bet Warren Buffett made against an active fund manager, ultimately proving that a long-term, 'boring' investment strategy can be just as successful.

The documentary also shows how to diversify risk over sectors, regions, and time, while impact investors Mark van Baal and former F1 World Champion, Nico Rosberg, outline how investing can in fact contribute to a better world.

In the course of the documentary, behavioural scientists and pioneers like Hersh Shefrin (Professor at Santa Clara University and best-selling author of "Beyond Greed and Fear") and Wendy De La Rosa (TED speaker and PhD Stanford University) explain how investing requires mental discipline to not get caught in your own brain's psychology of FOMO (Fear Of Missing Out), cognitive bias, confirmation bias and extrapolation bias. These can lead to mechanisms driving markets away from fundamental values as well as creating bubbles and crashes as witnessed by BBC Journalist Rory Cellan-Jones.

About flatexDEGIRO AG

flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates a leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution at top TIER 1 exchanges. Its technological edge as well as high levels of efficiency and strong economies of scale allows flatexDEGIRO to continuously improve its value proposition to clients, including commission-free brokerage.

With more than 2 million customer accounts and over 90 million securities transactions settled in 2021, flatexDEGIRO is the largest retail online broker in Europe. In a time of bank consolidation, low interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to grow its customer base to 7-8 million customer accounts, settling 250-350 million transactions per year - even in years with low volatility.

More information via https://www.flatexdegiro.com/en

Additional features:

Picture: https://eqs-cockpit.com/c/fncls.ssp?u=a07f12c4555ef094194edefc9bbf46ae

Subtitle: We challenge the biggest misconceptions about investing

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information please contact:
Achim Schreck
Head of IR & Corporate Communications
flatexDEGIRO AG
Rotfeder-Ring 7
D-60327 Frankfurt/Main
Tel. +49 (0) 69 450001 0
achim.schreck@flatexdegiro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye